

A3 trihydroxyvitamin D<sub>3</sub>, 22-oxa-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and 2 $\beta$ -  
(3-hydroxypropyloxy)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>..

---

REMARKS


The above claim amendments are made to eliminate improper multi-dependencies under U.S. practice so as to conform with 37 C.F.R. 1.75(c) in order to ensure examination of all claims. The amendments are not "narrowing" amendments. The scope of the claims has not been reduced; no limitations have been added and none are intended.

Applicants respectfully await the results of a first examination on the merits.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicants

By

  
Sheridan Neimark  
Registration No. 20,520

SN:jaa  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
F:\,Y\YUAS\Iida20\PTO\Amd Prelim.doc

Version with Markings to Show Changes Made

4. (Amended) The soft capsule formulation of any ~~one of claims 1 to 3~~claim 1 wherein ~~the base for the said~~ oily solution ~~is~~comprises at least one base material selected from the group consisting of fatty acid glycerides, propylene glycol fatty acid diesters, triacetin, polyethylene glycols and vegetable oils.

6. (Amended) The soft capsule formulation of any ~~one of claims 1 to 5~~claim 1 wherein the active vitamin D<sub>3</sub> is selected from 1 $\alpha$ -hydroxyvitamin D<sub>3</sub>, 24-hydroxyvitamin D<sub>3</sub>, 25-hydroxyvitamin D<sub>3</sub>, 1 $\alpha$ ,24-dihydroxyvitamin D<sub>3</sub>, 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>, 1 $\alpha$ ,24,25-trihydroxyvitamin D<sub>3</sub>, 22-oxa-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> and 2 $\beta$ -(3-hydroxypropyloxy)-1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub>..